A phase II trial of anlotinib and fulvestrant in patients with metastatic breast cancer previously treated with an aromatase inhibitor

被引：0
|
作者：
Wang, X. [1 ]
Huang, J. [1 ]
Wenyan, C. [2 ]
Sun, Z. [3 ]
Wei, S. [2 ]
Wang, L. [3 ]
机构：
[1] Zhejiang Canc Hosp, Dept Med Oncol, Hangzhou, Peoples R China
[2] Nanchang Peoples Hosp, Dept Breast Med Oncol, Nanchang, Jiangxi, Peoples R China
[3] Jiangxi Canc Hosp, Dept Breast Surg, Nanchang, Jiangxi, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.628
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
452P
引用
收藏
页码：S371 / S371
页数：1
相关论文
共 50 条
  • [31] Bosutinib in Combination With the Aromatase Inhibitor Exemestane: A Phase II Trial in Postmenopausal Women With Previously Treated Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer
    Moy, Beverly
    Neven, Patrick
    Lebrun, Fabienne
    Bellet, Meritxell
    Xu, Binghe
    Sarosiek, Tomasz
    Chow, Louis
    Goss, Paul
    Zacharchuk, Charles
    Leip, Eric
    Turnbull, Kathleen
    Bardy-Bouxin, Nathalie
    Duvillie, Ladan
    Lang, Istvan
    ONCOLOGIST, 2014, 19 (04): : 346 - 347
  • [32] Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium
    Manish R. Sharma
    Kristen Wroblewski
    Blase N. Polite
    James A. Knost
    James A. Wallace
    Sanjiv Modi
    Bethany G. Sleckman
    David Taber
    Everett E. Vokes
    Walter M. Stadler
    Hedy L. Kindler
    Investigational New Drugs, 2012, 30 : 1211 - 1215
  • [33] Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium
    Sharma, Manish R.
    Wroblewski, Kristen
    Polite, Blase N.
    Knost, James A.
    Wallace, James A.
    Modi, Sanjiv
    Sleckman, Bethany G.
    Taber, David
    Vokes, Everett E.
    Stadler, Walter M.
    Kindler, Hedy L.
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (03) : 1211 - 1215
  • [34] Phase II trial of temsirolimus in patients with metastatic breast cancer
    Gini F. Fleming
    Cynthia X. Ma
    Dezheng Huo
    Husain Sattar
    Maria Tretiakova
    L. Lin
    Olwen M. Hahn
    F. O. Olopade
    R. Nanda
    Philip C. Hoffman
    M. J. Naughton
    Timothy Pluard
    Suzanne D. Conzen
    Matthew J. Ellis
    Breast Cancer Research and Treatment, 2012, 136 : 355 - 363
  • [35] Phase II trial of temsirolimus in patients with metastatic breast cancer
    Fleming, Gini F.
    Ma, Cynthia X.
    Huo, Dezheng
    Sattar, Husain
    Tretiakova, Maria
    Lin, L.
    Hahn, Olwen M.
    Olopade, F. O.
    Nanda, R.
    Hoffman, Philip C.
    Naughton, M. J.
    Pluard, Timothy
    Conzen, Suzanne D.
    Ellis, Matthew J.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 136 (02) : 355 - 363
  • [36] Evaluation of fulvestrant in women with advanced breast cancer and progression on prior aromatase inhibitor therapy: a phase II trial of the North Central Cancer Treatment Group.
    Ingle, JN
    Rowland, KM
    Suman, VJ
    Mirchandani, D
    Bernath, AM
    Camoriano, JK
    Perez, EA
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S38 - S38
  • [37] Phase I trial of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.
    Possinger, K
    Schippinger, W
    Kiewe, P
    Lange, W
    Preiss, J
    Niederle, N
    Brossart, P
    Papke, J
    Freier, W
    de Velde, HV
    Schmid, P
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 66S - 66S
  • [38] Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
    Burstein, Harold J.
    Elias, Anthony D.
    Rugo, Hope S.
    Cobleigh, Melody A.
    Wolff, Antonio C.
    Eisenberg, Peter D.
    Lehman, Mary
    Adams, Bonne J.
    Bello, Carlo L.
    DePrimo, Samuel E.
    Baum, Charles M.
    Miller, Kathy D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (11) : 1810 - 1816
  • [39] Dasatinib (D) in previously treated metastatic colorectal cancer (mCRC) patients: A phase II trial of the University of Chicago phase II consortium
    Sharma, M.
    Wroblewski, K.
    Kozloff, M.
    Modi, S. S.
    Sleckman, B. G.
    Taber, D.
    Vokes, E. E.
    Stadler, W. M.
    Polite, B. N.
    Kindler, H. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [40] A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy
    Twardowski, Przemyslaw W.
    Beumer, Jan H.
    Chen, C. S.
    Kraft, Andrew S.
    Chatta, Gurkamal S.
    Mitsuhashi, Masato
    Ye, Wei
    Christner, Susan M.
    Lilly, Michael B.
    ANTI-CANCER DRUGS, 2013, 24 (07) : 743 - 753
12345